Skip to Main Content

Recombinant Human Serum Albumin (rHSA)

Exbumin®

Product Number 777HSA097
Form Lyophilized Powder
Origin Animal-Origin Free
Status GMP, Excipient

GMP excipient recombinant human serum albumin, supplied as a lyophilized powder for injectable drug formulation, cryopreservation, vaccine stabilization, and viral vector processing.

Replacing plasma-derived human serum albumin with Exbumin provides lot-to-lot consistency, lowers risk, and keeps added stabilizers such as octanoate and N-acetyl tryptophan out of your formulation.

10 g
$950.00
100 g
$8,170.00

Composition

Purity
≥98.0%
Endotoxin
≤0.100 EU/mg
Stabilizers
No preservatives or stabilizers
Storage
-20 °C (Powder)

Compliance

Status
AOF, Excipient
Manufacturing
cGMP, ISO 9001:2015
Facility
Junction City, KS
Documentation
Lot-specific CoA
View complete specifications

Product overview

A recombinant albumin excipient in a powder format.

Injectable formulations that use human serum albumin as a stabilizer have mostly used the plasma-derived material. Plasma-derived albumin carries adventitious agent risk, donor-pool variability, and TSE/BSE exposure that depends on donor screening. It is typically formulated with the stabilizers sodium octanoate (caprylate) and N-acetyl-DL-tryptophan, which are added to protect the protein during pasteurization. Supply is limited by plasma donor volumes and often runs through multiple donors and suppliers, and quality documentation varies by supplier. Regulatory scrutiny of blood-derived excipients keeps increasing.

Exbumin® is InVitria’s excipient recombinant human serum albumin, produced in the ExpressTec™ expression platform at the ISO 9001:2015-certified facility in Junction City, Kansas, under a cGMP-compliant quality management system with respect to 21 CFR Part 210/211.

Performance data

See the Data at a Glance

Bar chart comparing step yield through 0.22 micron filtration with buffer alone versus formulation with recombinant human serum albumin, for infectious potency, S protein and N protein

Fig. 1 · Downstream yield

Raises sterile-filtration step yield on rVSV

Merck and IAVI adapted the ERVEBO® purification process for an rVSVΔG-SARS-CoV-2 candidate using InVitria rHSA. Formulating the ultrafiltration product with rHSA before 0.22 µm filtration raised viral potency step yield from 42% to 74%, S protein from 27% to 59% and N protein from 41% to 72%, on equal-volume splits of the same feed.

Read the publication summary →
H3N2 and H1N1 M2SR vaccine virus titer after 0, 1, 8, and 16 freeze/thaw cycles in histidine buffer, histidine + CMC, and histidine + Exbumin rHSA

Fig. 2 · Freeze/thaw

Protects titer through repeated freeze/thaw

After 16 freeze/thaw cycles, H3N2 and H1N1 M2SR influenza vaccine virus titers in histidine buffer with Exbumin rHSA fell by only about 0.1–0.3 log10, versus roughly 1.5–2.0 log10 in histidine buffer alone. CMC protected less consistently than rHSA.

See the full presentation →
Healthy T cells per well after cryopreservation for two donors in 10% DMSO, or 2.5% DMSO with HSA, Exbumin, or no albumin

Fig. 3 · Cryopreservation

More healthy T cells post-thaw at reduced DMSO

Human T cells cryopreserved in 2.5% DMSO with 5% Exbumin yielded roughly 3–4× more healthy cells per well than the standard 10% DMSO solution, and more than clinical plasma-derived HSA at the same concentration. The application note includes a third donor and post-culture recovery.

Read the application note →

Featured Resources

The data behind the claims

Partner: Merck

Technical specifications

AttributeValue
Physical & Chemical
FormLyophilized powder
AppearanceWhite to off-white
Molecular weight~66.5 kDa
Purity≥98.0%
Endotoxin level≤0.100 EU/mg
ConcentrationReconstitute to working stock solution, 10 to 20% w/v recommended
pH6.50 to 7.50 upon reconstitution
SterilityPowder; sterile filter after reconstitution
Packaging10 g, 100 g, + scale packaging
Shelf life4 years from DOM (Powder)
Storage conditions-20 °C (Powder)
FormulationLyophilized from a buffered salt solution
Composition
Product nameExbumin®
BrandInVitria®
SKU / Product Number777HSA097
ProteinRecombinant Human Serum Albumin (rHSA)
ClassSerum Protein / Albumin, Excipient
SynonymsrHSA, HSA, ALB, Albumin, Human Albumin, SA, rHA
StatusRecombinant, Animal-Origin Free
Stabilizers/PreservativesNone
Regulatory
Animal-origin-freeYes
Production standardISO 9001:2015, cGMP-compliant facility
Country of originUSA (Junction City, KS)
Regulatory precedentNovel excipient in Merck’s ERVEBO® Ebola vaccine, 0.25% intramuscular, FDA and EMA, 2019
DocumentationCertificate of Analysis (request form) · Data Sheet · Guidelines for Use · Safety Data Sheet · Certificate of Origin and Animal-Free / TSE-BSE Statement · ISO 9001:2015 certificate · cGMP Statement · product-specific Technical Summary on request
Peer-reviewed validationCytotherapy 2023; Virus Research 2023; Vaccines 2025

Key Benefits

Excipient Specifications
Exbumin®: ≥98.0% purity, ≤0.100 EU/mg endotoxin, tested with consideration to the USP monograph.
Lower-DMSO T Cell Cryopreservation
At 2.5% DMSO with 5% Exbumin, roughly 3 to 4 times more healthy T cells than standard 10% DMSO.
Approved Vaccine Excipient
An excipient in Merck’s ERVEBO® Ebola vaccine, approved in 2019.
Virus Stabilization in Production
500 to 1500 mg/L is the general starting range; Exbumin increased influenza yield in VERO culture.
No Additives, No Donor Pool
Animal-free and blood-free, with no carrier, stabilizer, or preservative. Made under cGMP in Kansas.

How to order Exbumin®

Catalog purchase
10 g at $950 and 100 g at $8,170 on the InVitria catalog with direct checkout. Both ship as the lyophilized powder.
Purchase Order
Contact info@invitria.com or a Product Applications team member at InVitria to submit a PO directly.
Bulk pricing
Bulk and custom packaging beyond the 10 g and 100 g catalog formats, for clinical and commercial biopharmaceutical manufacturing. The bulk pricing form routes the request to InVitria. Working directly with InVitria is where volume-tier pricing, GMP supply commitments, and regulatory documentation support come from.
Regional distribution
Order through the Find a Distributor form. Exbumin is also available through Fisher Scientific, VWR, and the Labviva procurement platform. European customers can order with direct fulfillment from InVitria’s Rotterdam, Netherlands facility. Every channel ships the same product and Certificate of Analysis.

Common questions

Peer-Reviewed Publications

Exbumin® is built for these applications

Compare across the rHSA family

 
Concentration Lyophilized powder, reconstitute to 10 to 20% w/v 25% w/v sterile liquid 20% w/v sterile liquid Lyophilized powder, reconstitute to 10 to 20% w/v 25% w/v sterile liquid
Format 10 g, 100 g + scale 100 mL closed-system bag, 100 mL bottle + scale 100 mL and 1 L bottles 10 g, 100 g + scale 100 mL bottle + scale
Best for Serum-free cell culture media supplementation Injectable final-formulation excipient. Closed-system applications; 25% drop-in for plasma HSA Injectable final-formulation excipient. 20% drop-in for plasma HSA Injectable excipient rHSA for final formulation where lyophilized powder is preferred. Stem cell culture (iPSC/MSC/etc), lipid sensitive cell types, In Vitro Fertilization (IVF)
Grade GMP GMP, Excipient GMP, Excipient GMP, Excipient GMP
  Explore Cellastim S Explore Optibumin 25 Explore Optibumin 20 Explore Exbumin Explore Optibumin X